Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

Rational modulation of the immune response with biologics represents one of the most promising and active areas for the realization of new therapeutic strategies. In particular, the use of function blocking monoclonal antibodies targeting checkpoint inhibitors such as CTLA-4 and PD-1 have proven to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Proc Natl Acad Sci U S A
Auteurs principaux: Ramagopal, Udupi A., Liu, Weifeng, Garrett-Thomson, Sarah C., Bonanno, Jeffrey B., Yan, Qingrong, Srinivasan, Mohan, Wong, Susan C., Bell, Alasdair, Mankikar, Shilpa, Rangan, Vangipuram S., Deshpande, Shrikant, Korman, Alan J., Almo, Steven C.
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2017
Sujets:
PNAS Plus
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448203/
https://ncbi.nlm.nih.gov/pubmed/28484017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1617941114
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires